Literature DB >> 19931928

A low-dose hypersensitive keratinocyte loss in response to fractionated radiotherapy is associated with growth arrest and apoptosis.

Ingela Turesson1, Jan Nyman, Fredrik Qvarnström, Martin Simonsson, Majlis Book, Ingegerd Hermansson, Sunna Sigurdardottir, Karl-Axel Johansson.   

Abstract

BACKGROUND AND
PURPOSE: The existence of a hypersensitive radiation response to doses below 0.5Gy is well established for many normal and tumour cell lines. There is also evidence for hypersensitive tissue responses in acute skin damage and kidney function in mice. Recently, we have identified that a hypersensitive gammaH2AX response exists in human epidermis. The aim of this study was to investigate the dose-response of basal clonogenic keratinocytes in normal skin to fractionated radiotherapy with low dose fractions. MATERIALS: Skin punch biopsies were taken before and during radiotherapy from prostate cancer patients undergoing radiotherapy with a curative intent. Areas of epidermis receiving daily fractions of approximately 0.1, 0.2, 0.45 and 1.1Gy were biopsied on the same occasion to determine dose-response for each individual patient. In total, 89 cases were assessed either at 1, 2.5, 3, 4, 5 or 6.5 weeks in the treatment course. Biopsy sampling of another 25 patients was performed from areas receiving 0.45 and 1.1Gy per fraction at regular intervals throughout the 7-week treatment period. The number of basal keratinocytes per mm of the interfollicular epidermis was determined. The DNA damage response of the basal keratinocytes was investigated by immunohistochemical staining for molecular markers of growth arrest, mitosis and cell death, using p21, phospho-H3 and gammaH2AX, respectively. The number of stained keratinocytes in the basal layer was counted manually. The p21 staining was also quantified by digital image analysis.
RESULTS: The individual dose-response relationships revealed a low-dose hypersensitivity for reduction of basal keratinocytes throughout 7 weeks of radiotherapy (p<0.01). Growth arrest and cell proliferation assessed at 1 week and 6.5 weeks showed, in both cases, hypersensitive increase of p21 (p<0.01) and hypersensitive depression of mitosis (p<0.01). Manual counting and digital image analysis of p21 showed good agreement. Cell death was infrequent but increased significantly between 1 and 6.5 weeks and displayed a hypersensitive dose-response at the end of the treatment period.
CONCLUSIONS: A low-dose hypersensitivity in basal skin keratinocyte reduction is present throughout 7 weeks of radiotherapy. A persistent hypersensitive growth arrest response and cell killing mediate this effect. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19931928     DOI: 10.1016/j.radonc.2009.10.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  14 in total

1.  Mutation induction by inhaled radon progeny modeled at the tissue level.

Authors:  Balázs G Madas; Imre Balásházy
Journal:  Radiat Environ Biophys       Date:  2011-09-06       Impact factor: 1.925

2.  Quantification of patient-reported outcome measures of radiation-induced skin reactions for use in clinical trial design.

Authors:  N S Russell; E van Werkhoven; S B Schagen
Journal:  Support Care Cancer       Date:  2016-08-24       Impact factor: 3.603

3.  Transcriptional response of ex vivo human skin to ionizing radiation: comparison between low- and high-dose effects.

Authors:  Huguette Albrecht; Blythe Durbin-Johnson; Reem Yunis; Karen M Kalanetra; Shiquan Wu; Rachel Chen; Thomas R Stevenson; David M Rocke
Journal:  Radiat Res       Date:  2011-10-26       Impact factor: 2.841

4.  Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Authors:  Mario Balducci; Silvia Chiesa; Barbara Diletto; Giuseppe Roberto D'Agostino; Annunziato Mangiola; Stefania Manfrida; Giovanna Mantini; Alessio Albanese; Alba Fiorentino; Vincenzo Frascino; Berardino De Bari; Francesco Micciche'; Fiorenza De Rose; Alessio Giuseppe Morganti; Carmelo Anile; Vincenzo Valentini
Journal:  Neuro Oncol       Date:  2011-10-12       Impact factor: 12.300

5.  Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study.

Authors:  M Balducci; B Diletto; S Chiesa; G R D'Agostino; M A Gambacorta; M Ferro; C Colosimo; G Maira; C Anile; V Valentini
Journal:  Strahlenther Onkol       Date:  2014-01-17       Impact factor: 3.621

6.  A tissue graft model of DNA damage response in the normal and malignant human prostate.

Authors:  Taija M Af Hällström; Hongjuan Zhao; Junqiang Tian; Ville Rantanen; Stephen W Reese; Rosalie Nolley; Marikki Laiho; Donna M Peehl
Journal:  J Urol       Date:  2013-09-11       Impact factor: 7.450

Review 7.  Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy.

Authors:  Adeola Y Makinde; Molykutty John-Aryankalayil; Sanjeewani T Palayoor; David Cerna; C Norman Coleman
Journal:  Mol Cancer Res       Date:  2012-11-21       Impact factor: 5.852

8.  Impact of time interval and dose rate on cell survival following low-dose fractionated exposures.

Authors:  Shingo Terashima; Yoichiro Hosokawa; Eichi Tsuruga; Yasushi Mariya; Toshiya Nakamura
Journal:  J Radiat Res       Date:  2017-11-01       Impact factor: 2.724

9.  The role of nitric oxide radicals in removal of hyper-radiosensitivity by priming irradiation.

Authors:  Nina Jeppesen Edin; Joe Alexander Sandvik; Hilde Synnøve Vollan; Katharina Reger; Agnes Görlach; Erik Olai Pettersen
Journal:  J Radiat Res       Date:  2013-05-17       Impact factor: 2.724

10.  Exposure to Carbon Ions Triggers Proinflammatory Signals and Changes in Homeostasis and Epidermal Tissue Organization to a Similar Extent as Photons.

Authors:  Palma Simoniello; Julia Wiedemann; Joana Zink; Eva Thoennes; Maike Stange; Paul G Layer; Maximilian Kovacs; Maurizio Podda; Marco Durante; Claudia Fournier
Journal:  Front Oncol       Date:  2016-01-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.